I. Introduction {#sec0001}
===============

The human cell is a complex network of membranes and protein enclosed in a membrane lipid bilayer. The interactions within and associated with such biomembrane bilayers have profound consequences for the organism as a whole; a single defect in just 1 of the potential 30--40,000 gene products made by each cell can cause devastating, if not fatal, effects for the whole organism. In addition to this, humans pass genetic information onto their offspring and, with it, any genetic mutations or polymorphisms. It is believed that at least 1 in 10 people have, or will eventually develop, a disease caused by mutation or variation at the gene level. Understanding how genetic mutations increase risk for human disease is critical in our understanding and treatment of the majority of human ailments that are caused by interactions between the organism and the environment.

This review focuses on the research undertaken in the past 30 years relating to the molecular mechanisms that underlie membrane trafficking within eukaryotic cells. We address mechanisms and factors that control protein progression through the secretory and internalization pathways and highlight key human diseases that illuminate mechanisms of membrane trafficking. In addition, current and future strategies for therapeutic intervention in such genetic disorders are considered.

II. Principles of Membrane Traffic in Eukaryotic Cells {#sec0002}
======================================================

Common to all eukaryotic cells is the presence of multiple biomembrane lipid bilayer compartments, or organelles, which are maintained by specific protein--protein and protein--lipid interactions. Such interactions are maintained within each compartment in spite of continuous trafficking of membrane‐bound and soluble components to different intracellular locations, and for secretion from the cell. In the majority of cases, this transfer of material occurs through vesicular movement: fission, docking, and fusion of membrane bilayer‐enclosed intermediates occurs between donor and acceptor compartments ([@bib0263]). Proteins, including membrane‐bound receptors, secreted enzymes, and antibodies, begin their journey by entering the early secretory pathway at the endoplasmic reticulum (ER). From here they are transported through the Golgi apparatus and finally distributed to their final destination such as other intracellular organelles, the plasma membrane, or the extracellular environment.

But how does a specific protein "know" how to reach a specific cellular destination when hundreds of newly synthesized, different molecules require specific transport and targeting? Many of these transport intermediates or vesicles, whether derived from the ER, other internal organelles, or the plasma membrane, are "coated" with unique protein complexes, tethering factors, and regulatory factors that ensure correct targeting to an acceptor compartment. Vesicle coat proteins, such as the clathrin or coat protein (COP) complexes, are relatively well studied. Such complexes are assembled onto the cytoplasmic face of donor compartments to facilitate the fission of transport intermediates. Allied with these coat proteins are different molecules that mediate recognition of cytoplasmic motifs in cargo proteins either directly (e.g., transmembrane proteins) or indirectly (e.g., soluble secreted enzymes).

The SNARE hypothesis is central to our understanding of vesicular targeting to intracellular compartments ([@bib0294], [@bib0328]). Initially uncovered in a screen for intra‐Golgi transport docking and fusion regulators, the SNARE (soluble *N*‐ethylmaleimide‐sensitive fusion attachment protein receptor) proteins have been found to regulate different membrane interactions in all eukaryotes via a highly conserved mechanism for membrane trafficking based on accessory docking and fusion regulators. SNARE proteins are present on both the vesicle (vesicular or v‐SNARE) and the acceptor (target or t‐SNARE) and comprise coiled‐coil domains that assemble to facilitate vesicle docking and membrane fusion ([@bib9001], [@bib9002]).

In conjunction with SNARE proteins, small Ras‐related Rab GTPases are implicated in further ensuring the fidelity of vesicle docking and fusion ([@bib0258]). These 20‐ to 25‐kDa proteins are GTP‐hydrolyzing enzymes that act to recruit different proteins or effectors to membranes in a GTP/GDP‐regulated manner ([@bib0059]). Rab GTPase activity and protein conformation are regulated by interaction with soluble and membrane‐bound proteins; such regulators can also tether vesicles to acceptor membranes and mediate intracellular signaling.

III. Secretory Pathways {#sec0003}
=======================

A. Early Secretory Pathway {#sec0004}
--------------------------

### 1. ER Quality Control {#sec0005}

The endoplasmic reticulum (ER) is the first stage of quality control along the secretory pathway. Proteins destined for secretion (e.g., hormones), the plasma membrane (e.g., membrane‐bound receptors), or other intracellular membrane compartments such as the lysosome (e.g., lysosomal proteases) are cotranslationally inserted into the ER lumen through a protein complex referred to as the Sec61 translocon ([@bib0344]). Here they are folded, glycosylated, and, in some cases, assembled into oligomeric complexes before passage along the secretory pathway to the Golgi apparatus. Proteins in transit through the Golgi apparatus can be subject to the action of proteases and glycosylating enzymes, resulting in modifications characteristic of passage through a specific subcompartment. Secreted proteins and lipids are finally sorted at the *trans*‐Golgi network (TGN) to their final destination. The ER therefore plays a rate‐determining role as the first compartment along this route by ensuring proteins are assembled and folded correctly before ER export. The ER thus contains a variety of resident enzymes, lectins, and chaperones that perform the quality control steps involved in protein assembly and export. A protein that does not pass this initial quality assessment, perhaps because of a mutation that does not allow correct folding or oligomerization, will be retained within the ER and subsequently degraded ([Section III.A.2](#sec0006){ref-type="sec"}). In severe cases, where the ER cannot remove such a misfolded protein, an ER stress response is initiated that results in apoptosis, or cell suicide, in an attempt to preserve the functionality of the tissue or organ ([@bib0159]).

The effectiveness of the ER as a quality control checkpoint along the secretory pathway is reflected by the large variety of genetic mutations in proteins that cause aberrant ER retention, accumulation, or activation of the ER stress response (see [Table I](#tbl0001){ref-type="table"} ). An important human disease that highlights this phenomenon is cystic fibrosis (CF): nearly 70% of CF patients have a 3‐bp deletion in the gene encoding the chloride channel transmembrane regulator (CFTRΔF508) ([@bib0022]), which causes defective chloride transport across the apical epithelial membrane and enhanced sodium absorption through various basolateral membrane Na^+^/K^+^‐ATPases. These changes lead to a net increase in water absorption and a characteristic thickening of lung mucus in CF patients. Whereas both wild‐type CFTR and CFTRΔF508 interact with ER chaperones, mutant CFTR shows prolonged interaction with ER chaperones Hsp70/Hdj‐1 and calnexin ([@bib0005], [@bib0276]).Table IHuman Diseases and Associated Membrane Trafficking DefectsHuman diseaseProteinMembrane trafficking defectClinical featuresReferencesOMIM[a](#tblfn0001){ref-type="table-fn"}α1‐Antitrypsin deficiencyα1‐AntitrypsinInhibited export from the ER of this secreted protein. Lung and liver damage by proteasesEmphysema and liver cirrhosis([@bib0273])107400Acute myeloid leukemiaEndophillin IIClathrin--coated pit formationLeukemia([@bib0084], [@bib0154], [@bib0244], [@bib0355])604465Alzheimer\'s diseasePresenilin 1*Presenilin 1*--involved in cleavage and trafficking of amyloid precursor protein to plasma membraneNeurodegenerative disorder([@bib0361])104300Tau*Tau* -- microtubular stability through formation of aggregatesAutosomal dominant polycystic kidney disease (ADPKD)Polycystin‐1 or 2Causes a defect in E‐cadherin assembly and basolateral traffickingRenal cysts in kidney and other tissues leading to end‐ stage renal failure([@bib0045])173900Autosomal dominant retinitis pigmentosaRhodopsinInhibited interaction of rhodopsin and ARF4, leading to inhibited post‐Golgi delivery to rod outer segmentNarrowing of visual fields, night blindness([@bib0074])180380Autosomal dominant ventricular tachycardiaRyanodine receptorMutations in lumenal and transmembrane domainsCardiac arrhythmia, hyperthermia([@bib0392])604722Autosomal recessive primary hyperoxaluriaAlanine‐glyoxylate aminotransferaseMistargeting of peroxisomal proteins to mitochondriaKidney disease([@bib0065])259900Aβ‐lipoproteinaemiaMTPER retention thus preventing ApoB secretionVascular disease([@bib0319])200100Batten\'s diseaseCLN1‐CLN8Group of gene products implicated in regulating the processing and targeting of lysosomal and synaptic proteinsNeurological disease([@bib0265])204200Breast cancerCaveolin‐1Deletion or dominant negative mutation of caveolin‐1 promotes tumor progressionBreast cancer([@bib0030]; Williams and Lisanti, 2005)601047Brugada syndromeSCN5A, α subunit of cardiac sodium channelER retention of sodium channel subunits and defective cell surface sodium transportCardiac disease([@bib0015])601144Charcot‐Marie‐Tooth disease, demyelinating, type 1BMyelin protein zero gene, MPZER retention of integral membrane proteinNeurological and degenerative muscle disease([@bib0130], [@bib0221])118200Charcot‐Marie‐Tooth disease, axonal, type 2A1KIF1BMicrotubular transport of synaptic vesiclesNeurological and degenerative muscle disease([@bib0399])118210Chediak‐Higashi syndrome (CHS)CHS1/LystLyst involved in regulation of protein secretion from lysosomes -- enlarged lysosomesPartial albinism, recurrent bacterial infections, impaired chemotaxis and abnormal natural killer cell function([@bib0321], [@bib0372])214500Choroideremia (CHM)Rab Escort Protein 1 (REP1)RAB27a remains cytosolic due to defective geranylgeranyl modification in CHM lymphoblastsX‐linked form of retinal degeneration([@bib0314])303100Combined factors V and VIII deficiencyERGIC‐53/p58 C‐type lectinER retention and defective secretion of factors V and VIIIBlood disease([@bib0249])227300Congenital Finnish nephritic syndromeNephrin (NPHS1), podocin (NPHS2)ER retentionKidney inflammation([@bib0160], [@bib0174])256300 600995Congenital hyperinsulinismPancreatic ATP‐sensitive potassium channel (K‐ATP)ER or Golgi retention of K‐ATP due to mutations in its sulfonylurea‐1 (SUR1) subunitExcess insulin leading to hypoglycaemia([@bib0087], [@bib0389])602485Congenital hypothyroid goiterThyroglobulinER storage disease. Thyroglobulin is misfolded and accumulates in ERConstipation, large tongue, swelling around the eyes, failure to suckle, mental retardation([@bib0139], [@bib0163])188450Congenital sucrase‐isomaltase deficiencySucrase‐isomaltaseER retention instead of brush border membrane localizationGastrointestinal disease(Naim *et al*., 1998)222900Cystic fibrosisCystic fibrosis transmembrane conductance regulator (CFTR) chloride channelTrafficking of the chloride channel to the plasma membrane is defectiveMulti‐organ disease, most commonly lungs and pancreas([@bib0134])219700Demyelinating polyneuropathyEEA1Autoantibody against EEA1Limb weakness([@bib0318])605070Dent\'s diseaseCLC‐5 voltage‐gated chloride channelInhibited post‐Golgi transport to cell surfaceProgressive renal failure([@bib0042], [@bib0209])300009Diabetes insipidus (nephrogenic)Vasopressin V2 receptorER storage disease leading to retention of receptor in the ERExcessive water secretion through kidneys (diabetes insipidus)([@bib0163], [@bib0235])304800Diabetes mellitus (Type 2)Insulin receptorFunctional defects or ER retentionDiabetes mellitus; polyuria, polydipsia, tiredness, increased appetite([@bib0155])125853Dubin‐Johnson syndromeMRP2ER retentionLiver disease([@bib0234])237500Fabry\'s diseaseα‐Galactosidase AIn this fat storage disorder, lysosomal α‐galactosidase is retained in the ER, preventing degradation of glycosphingolipidsCloudiness of eyes, burning sensation in hands and feet, skin blemishes, renal failure, myocardial infarction([@bib0097], [@bib0114])301500Familial hemophagocytic lymphoschistiocytosis (FHL)Perforin*Perforin* -- defective CTL (cytotoxic T lymphocytes) mediated killingImmunodeficiency([@bib0100], [@bib0336])603553Munc 13--4*Munc 13--4* -- inhibited release of secretory lysosomes from CTLsFamilial hypercholesterolemiaLow density lipoprotein receptor (LDLR)ER retention and degradation of LDLRIncreased blood cholesterol, atherosclerosis, heart disease([@bib0069])143890Familial intrahepatic cholestasisMDR3ABC transporter of phosphatidylcholine out of cellLiver disease([@bib0078])602347Griscelli syndromeMyosin Va or Rab27AInhibited transport of melanosomes to plasma membrane in melanocytesAlbinism, silvery hair, neurological defects, immunodeficiency([@bib0225])214450 607624Hereditary myeloperoxidaseMPOER retention and degradationCancer, immunodeficiency([@bib0070])606989Hereditary hemochromatosisHemochromatosis (HFE)Mutant HFE fails to bind transferrin receptor at cell surface, resulting in iron overloadLiver cirrhosis, diabetes mellitus, cardiomyopathy([@bib0231])235200Hereditary spherocytosisChloride/bicarbonate anion exchangerMisfolding and accumulation in the ER without rapid degradation or severe aggregationBlood disease([@bib0284])182900Hermansky‐Pudlak syndromeβ subunit of AP3*AP3* -- compromised lysosomal traffickingPartial albinism, bleeding, ceroid accumulates in lysosomal structures([@bib0076], [@bib0147])203300RabGGT‐α subunit*RabGGT‐α* -- inhibited Rab prenylation and membrane associationHuman neutropeniaNeutrophil elastase Occasionally other genes*Cyclic neutropenia.* Excessive routing of NE to granulesAlternate 21 day cycling of neutrophils and monocytes([@bib0019], [@bib0021], [@bib0145])162800*Severe congenital neutropenia*. Impaired association with AP3; NE redirected from lysosome to plasma membranePromyelocytic arrest in bone marrow202700Huntington\'s diseaseHuntingtin (htt)Microtubular transport of BDNFNeurodegeneration([@bib0116])143100I‐cell diseaseNAGT1 phosphotransferaseDefect in mannose‐6‐ phosphate addition to lysosomal enzymes resulting in aberrant targetingNeurological disease([@bib0020])252500Laron syndromeGrowth hormone receptorLow levels of cell surface protein caused by ER retentionDwarfism([@bib0381])245590Leukocyte adhesion deficiency type ICD18Leukocyte rolling and adhesion during immune reactionRecurrent bacterial and fungal infections, poor wound healing([@bib0140], [@bib0219])116920Limb girdle muscular dystrophy 1C, rippling muscle disease, distal myopathyCaveolin‐3Abnormal caveolin‐3 traps normal caveolin‐3 in the Golgi of skeletal muscle cellsMuscle diseases([@bib0382])601253LissencephalyLIS1 or doublecortinMicrotubular motor function or stabilization of microtubulesRetardation, epilepsy([@bib0286])607432*Listeria monocytogenes* infectionHepatocyte growth factor receptor (HGFR)HGFR on the host cell internalizes bacteria via binding to the surface protein internalin BSymptoms of food poisoning([@bib0192])164860Long QT‐2 syndromeHuman ether‐a‐go‐go (HERG) potassium channelER retention of HERG preventing trafficking to cell surfaceAbnormal electrical cardiac impulses and ventricular tachycardia([@bib0178])192500Menkes\' diseaseATP7A (Menkes disease protein)Mislocalization and/or degradation of this copper transporter leads to copper deficiencyMental retardation, skeletal abnormalities, kinky hair. Usually lethal before the age of 3([@bib0212])309400Multiple exostoses syndromeGolgi‐localized EXT1 and EXT2 complexMutations reducing glucoronyltransferase and *N*‐acetyl‐D‐ glucosaminotransferase activity inhibit post‐ER transport of EXT1/EXT2Skeletal dysplasia, connective tissue disorder([@bib0223])133700Nephrogenic diabetes insipidusWater channel aquaporin‐2ER retention; some AQP2 mutants can leave ER using chemical chaperonesExcessive water secretion through kidneys (dilute urine and excess water loss)([@bib0349])125800Niemann‐Pick disease type CNPC1Lysosomal accumulation of LDL‐derived cholesterolNeurodegenerative disease(Liscum, 2000)257220Occipital horn syndromeATP7A (Menkes disease protein)ER retention of ATP7A results in a milder form of Menkes diseaseMental retardation, skeletal abnormalities([@bib0157], [@bib0283])304150Ocular and oculocutaneous albinismTyrosinase, GPCR‐like OA1 gene productUnstable or mislocalized proteinsEye pigmentation defects([@bib0062])300500Oculocerebrorenal syndrome of LoweOCRL1Perturbed endosome‐to‐ TGN traffickingCataracts, mental retardation, renal failure([@bib0207])309000Osteogenesis imperfectaType I collagenDefective trafficking or ER retention of collagenBrittle bones and teeth, hearing loss([@bib0278])166200Paraneoplastic stiff‐person syndromeAmphiphysin IClathrin‐coated vesicle formation compromisedAutoimmune disease([@bib0067])184850Pelizaeus‐Merzbacher diseaseProteolipid protein (PLP) geneER retention leading to ER stress signaling and apoptosisNeurological disease([@bib0121])312080Pendred syndromePendrin (anion transporter)ER retention of a cell surface iodide transporterHypothyroidism, deafness([@bib0353])274600Persistent hyperinsulinemic hypoglycemia of infancy (PHHI)Potassium channel (Kir6.2) and sulfonylurea receptor (SUR1) subunitsER or TGN retention of a cell surface potassium channel involved in insulin secretionHyperinsulinism, hypoglycemia([@bib0352])601820Prion diseasesPrion protein (PrP)Abnormal PrP accumulate in the ER; perturbed trafficking to cell surfaceNeurodegenerative disorders([@bib0129])176640Rhizomelic chondrodysplasia punctaPex7Defective import of peroxisomal matrix proteinsSkeletal defect, neurological disease([@bib0356])215100Stargardt‐like macular dystrophyABCA4 gene; vitamin A transportDefective localizationBlindness([@bib0091], [@bib0342])248200Usher\'s syndromeMyosin VIIAMelanosome transportBlindness, deafness([@bib0203])276903Wilson\'s diseaseATP7B (Wilson\'s disease protein)ER retention and inhibited secretion of copper‐containing enzymes from liverNeurological disease, liver cirrhosis(Cox and Gitlin, 2003; Moore, 2002)277900Wiskott‐Aldrich syndromeWiskott‐Aldrich syndrome protein (WASP)WASP regulation of actin cytoskeletonImmunodeficiency, autoimmune disease, hematologic malignancy([@bib0037])301000[^2]

Another key example of misfolded proteins being retained in the ER is Menkes disease, a rare and severe X‐linked recessive disorder characterized by abnormal hair, neurodegeneration, and early childhood fatality. The disease is due to copper deficiency along the secretory pathway caused by the malfunctioning of the Menkes disease protein (ATP7A). This gene product is a multiple transmembrane domain protein and copper transporter of the P‐type ATPase family responsible for translocating copper ions across intracellular membranes. Fibroblasts from patients who carry a genetic mutation resulting in the G1019D amino acid substitution in ATP7A show ER retention of this P‐type ATPase ([@bib0161]).

Three forms of Menkes disease can arise from different mutations in the ATP7A gene: premature stop codons, deletions, or splicing defects. These can prevent ATP7A function and/or trafficking. Classical Menkes disease is the most common and fatality usually results by the age of 3 years. In two other nonfatal forms of Menkes, mild and occipital horn syndrome, ATP7A maintains the ability to transport copper ions across intracellular membranes, although trafficking to the plasma membrane can be compromised ([@bib0182]).

ATP7A is ubiquitously expressed and is the major copper transporter in cells of the intestine, kidney, and brain. In the liver, however, the major copper transporter is the Wilson\'s disease protein, ATP7B ([@bib0035]). This second P‐type ATPase shares strong similarity with ATP7A and also translocates copper ions across membranes. Although these gene products share functional similarities, mutations in ATP7B result in copper accumulation in the liver and brain.

Familial hypercholesterolemia is an autosomal dominantly inherited disease caused by mutations in the low‐density lipoprotein receptor (LDLR), leading to premature atherosclerosis and coronary heart disease. In healthy individuals, the LDLR is expressed on the surface of cells, where it binds circulating LDL particles and promotes uptake and cellular metabolism of its constituents, which includes cholesterol. In these patients, LDLR alleles display amino acid substitutions ([@bib0043], [@bib0151]), truncations ([@bib0187]), or missense mutations ([@bib0188]), which can result in ER retention and degradation.

The point mutation at residue 209 of the insulin receptor compromises the ability of the receptor to dimerize correctly within the ER, therefore leading to ER retention. Decreased plasma membrane levels of insulin receptor cause inhibited insulin binding after stimulus by a meal, and subsequent elevations in plasma glucose levels. This then leads to type II diabetes mellitus ([@bib0155]).

A number of human diseases can induce the ER stress response. Here, the mutant protein is retained within the ER, resulting in either dilation of the organelle, such as in congenital hyperthyroidism ([@bib0224]) and hypofibrinogenemia ([@bib0040]), or chronic ER stress as is the case for hereditary emphysema ([@bib0272]). In Pelizaeus‐Merzbacher disease, an X‐linked leukodystrophy disease, ER accumulation of proteolipid protein (PLP) results in oligodendrocyte apoptosis ([@bib0121]) and the subsequent disruption of white matter formation in the brain observed in humans and mouse models. PLP is a central nervous system protein that is the major component of myelin and, when expressed in cultured fibroblasts, is localized to the plasma membrane ([@bib0120]). The link between PLP and the ER stress response provides a tool for elucidating the cellular response to misfolded protein accumulation ([@bib0345]).

### 2. ER‐Associated Degradation {#sec0006}

Accumulation of proteins within the ER, leading to blockage of protein secretion, is an unwanted cellular property and mechanisms have evolved to overcome such events. This disposal of unwanted proteins is termed ER‐associated degradation (ERAD) ([Fig. 1](#fig0001){ref-type="fig"} ). As recently as the early 1990s, it was still believed that aberrant proteins were degraded within the ER ([@bib0106]); however, current models suggest that aberrant ER‐retained proteins actually undergo retrotranslocation and subsequent degradation in the cytoplasm. Retrotranslocation has been proposed to occur through the same "pore" used to translocate nascent proteins into the ER lumen during translation, namely the Sec61 translocon ([@bib0024], [@bib9004]).Fig. 1Quality control of protein assembly within the endoplasmic reticulum. Proteins destined for the secretory pathway (this example shows a transmembrane protein) are cotranslationally translocated from the ribosome into the lumen of the endoplasmic reticulum (ER) through a portal referred to as the Sec61 translocon. As the newly synthesized protein enters the ER, quality control mechanisms in the form of protein chaperones bind to it and fold it to its correct conformation. Further processing occurs through interactions with other chaperones before the successfully folded protein is loaded into COPII‐coated vesicles and shuttled from the ER to the Golgi apparatus. However, if the protein carries a mutation that causes it to take on an aberrant conformation the ER chaperones will trigger a misfolded protein response. This has two outcomes: either the chaperones will remain bound to the misfolded protein, preventing its escape from the organelle (ER retention), or the protein will be ubiquitinated and retrotranslocated through the Sec61 complex for proteasomal degradation in the cell cytoplasm. A number of human genetic diseases are a result of key proteins failing to traffic through the secretory pathway and as a consequence are retained or degraded in this manner.

Various yeast and mammalian proteins have been shown to be retrotranslocated from the ER and degraded within the cytoplasm in a proteasome‐dependent manner, including the budding yeast proteins carboxypeptidase Y, and a mutant pro‐α‐factor. When a mammalian protein such as CFTR is expressed in budding yeast, it matures relatively slowly within the yeast ER, leading to retrotranslocation to the cytoplasm and degradation ([@bib0371]). A further example is that of α~1~‐antitrypsin deficiency. α~1~‐Antitrypsin is responsible for inactivating the enzyme elastase produced by lung neutrophils. In this inherited disease, a mutated form of α~1~‐antitrypsin is retrotranslocated and degraded in proteasomes, leading to retention of active elastase in lung tissues and thus is a cause of lung emphysema ([@bib0298]).

However, retrotranslocation and proteasomal degradation may not be functionally coupled processes. Pharmacological inhibitors that cause proteasome inactivation lead to egress of molecules such as MHC class I ([@bib0376], [@bib0377]), ribophorin ([@bib0077]), and carboxypeptidase Y ([@bib0025]) from the ER to the cell cytoplasm. In contrast, inhibition of protein ubiquitination results in the retention of such molecules within the ER. [@bib0307] suggest that two distinct proteasome‐regulated pathways mediate degradation of retrotranslocated β‐amyloid precursor protein.

Interestingly, endocytosed toxins that target key cytosolic factors appear to use the ERAD pathway to move out of the ER and into the cytosol ([@bib0068], [@bib0133]). Cholera and ricin toxins are routed from the cell surface through the Golgi apparatus and to the ER before being retrotranslocated into the cell cytosol. It is believed that the unusually low lysine content of these protein toxins prevents subsequent ER‐associated ubiquitination for degradation by the cytosolic proteasome.

### 3. Protein Traffic between the ER and Golgi Apparatus {#sec0007}

Protein cargo is shuttled between the ER and Golgi within vesicular intermediates or 50‐nm‐diameter spherical vesicles containing *co*at *p*rotein complexes such as COPI or COPII. Initially discovered in mammals and yeast ([@bib0156], [@bib0216], [@bib0253], [@bib0295]), COP complexes are required for the formation of vesicles at the ER, ER--Golgi intermediate compartment (ERGIC), and Golgi apparatus. COP recruitment to membranes facilitates the specific capture, packaging, transport, and delivery of membrane‐bound and soluble protein cargo to an acceptor compartment.

COPII recruitment to sites on the smooth ER initiates the formation of anterograde (forward) transport vesicles. These COPII vesicles move from the ER to the ERGIC, or vesicular tubular clusters (VTCs). From here, COPI‐coated vesicles are thought to mediate the continued anterograde movement from the ERGIC to the *cis* face of the Golgi apparatus ([@bib0303]).

The Sar1p GTPase regulates COPII vesicle formation via interaction with the Sec12p guanine exchange factor (GEF). Sec12p‐mediated activation of Sar1p to a GTP‐bound form leads to recruitment of the Sec23p--Sec24p heterodimer to membranes; this also initiates protein cargo selection within the ER and recruitment of v‐SNAREs such as Bet1p and Bos1p. Binding of Sec23p--Sec24p mediates further recruitment of the Sec13p--Sec31p complex. This COPII complex then acts as a protein scaffold that causes deformation of the membrane, resulting in vesicular fission, with anterograde movement of protein cargo‐containing COPII vesicles to the ERGIC. COPII docking at an acceptor compartment is thought to trigger Sec23p function, causing a conformational change in Sar1p and GTP hydrolysis and dissociation or uncoating of the COPII complex. Thus COPII vesicle docking and fusion with an acceptor compartment are mediated by cognate v‐SNARE/t‐SNARE interactions ([@bib0164], [@bib0176], [@bib0220], [@bib0350]).

A severe hereditary bleeding disorder called combined deficiency of factor V factor VIII (F5F8D) highlights the functional importance of trafficking between the ER and ERGIC. Some F5F8D patients are deficient in the ERGIC‐localized ERGIC‐53 (LMAN1) protein and display defective secretion of the factor V and VIII clotting factors. ERGIC‐53 is a mannose‐binding lectin that acts as a "cargo receptor" and recycles between the ER and ERGIC ([@bib0245], [@bib0249]). However, ∼30% of F5F8D patients show normal levels of ERGIC‐53/LMAN1, but are deficient in an associated protein, MCFD2, another ERGIC resident that interacts with ERGIC‐53/LMAN1 in a calcium‐dependent manner ([@bib0398]).

Small intestinal cells called enterocytes absorb fats and fat‐soluble vitamins from food in the form of fatty acids and monoglycerides. The fats enter the lumenal surface of absorptive enterocytes by free diffusion across their membranes, and emerge from the basolateral surface as particulate structures referred to as chylomicrons. Formation of chylomicrons occurs within the ER and Golgi apparatus by vesicular transport before being trafficked from the Golgi to the plasma membrane. Chylomicron retention disease (CMRD), Anderson disease, and a neuromuscular disorder, CMRD associated with Marinesco‐Sjögren syndrome (CMRD‐MSS), are examples of inherited diseases that result in compromised fat absorption, low blood cholesterol, and severely depleted blood chylomicron levels. [@bib0153] identified eight mutations in the Sar1p gene product and COPII component associated with these lipid absorption diseases, thus strongly implicating a role for the COPII vesicular transport system in the movement of dietary fats from the intestine to the circulating bloodstream.

COPII mediates anterograde traffic from the ER to the Golgi apparatus; however, COPI vesicles appear to function primarily in the retrograde (backward) transfer of proteins from the Golgi and ERGIC back to the ER. This retrograde traffic is necessary for recovering escaped ER resident proteins, coat and SNARE proteins that have arrived at the ERGIC and Golgi from COPII vesicles, or glycosylation enzymes that have been incorrectly modified ([@bib0086], [@bib9000]). The Golgi‐associated COPI coatomer is a complex of seven polypeptides: α‐, β‐, β′‐, γ‐, δ‐, ε‐, and ζ‐COP gene products, which interact with the donor membrane to form COPI vesicles. Vesicle formation is triggered by the GTPase ADP‐ribosylation factor 1 (ARF1), which recruits COPI coatomer to the donor membrane. Transmembrane proteins containing cytoplasmic lysine‐based motifs such as KKXX or KXKXX, or soluble proteins containing the C‐terminal KDEL motif, are recycled by COPI‐coated vesicles from the Golgi apparatus back to the ER. The KDEL motif, present in soluble ER chaperones such as BiP and protein disulfide isomerase, is recognized by the membrane‐bound KDEL receptor ([@bib0215]). In both cases, cytoplasmic motifs in these transmembrane proteins are recognized and bound by COPI coatomer, promoting inclusion into vesicles destined for the ER. Actin microfilaments are also involved in this retrograde transport step ([@bib0364]). This Golgi--ER step is regulated by the GTPase Cdc42 and N‐WASP protein ([@bib0210]), factors previously implicated in actin‐linked processes at the plasma membrane.

Live imaging of cells expressing an engineered fluorescent and temperature‐sensitive vesicular stomatitis virus G‐glycoprotein (ts045VSVG) demonstrated sequential action of COPII‐ and COPI‐coated vesicles ([@bib0303]). VSVG accumulated in structures close to the ER that contained intermediate compartment resident proteins. These structures then matured into vesicles that contained COPI proteins. [@bib0335] showed that this "segregation" between COPII and COPI vesicles occurred at a location in close proximity to exit sites on ER membranes.

A COP‐independent mechanism has also been implicated in retrograde traffic between the Golgi apparatus and the ER. The Rab6 GTPase is implicated in regulating the movement of bacterial Shiga toxin B fragment (STB) via a retrograde step from the Golgi apparatus to the ER. Expression of a dominant‐negative GDP‐bound form of Rab6 inhibited STB retrograde movement, whereas COPI transport was unaffected ([@bib0374]).

### 4. Intra‐Golgi Transport {#sec0008}

The Golgi apparatus is composed of flattened cisternae and membrane compartments that are closely juxtaposed in a stack‐like appearance. In mammalian cells these stacks are positioned end‐to‐end, forming a ribbon‐like structure near the nucleus ([@bib0016]). The Golgi apparatus is a highly dynamic organelle sited at the hub of the secretory pathway with key processing and sorting functions. The Golgi is a polarized structure with proteins and lipids from the ER received at the *cis* side, followed by the *medial* and *trans* subcompartments, where further glycosylation modifications occur; the *trans*‐Golgi network (TGN) is the final subcompartment where sorting and packaging events take place. The Golgi apparatus also sorts proteins and lipids bound on a retrograde pathway from the *cis*‐Golgi back to the ER. In addition, proteins can also return to the TGN from the endomembrane/lysosomal system ([Fig. 2](#fig0002){ref-type="fig"} ).Fig. 2The secretory pathway and vesicular trafficking. Protein enters the secretory pathway at the endoplasmic reticulum (ER) and is trafficked in COPII‐coated vesicular structures to the intermediate compartment (ERGIC/VTC), from which COPI‐coated vesicles carry it to the *cis* face of the Golgi. Cargo protein (C) continues along the secretory pathway through the Golgi apparatus to the *trans*‐Golgi network (TGN). Retention signals in ER resident proteins (R) ensure they undergo retrograde trafficking from the Golgi in COPI vesicles. Retrograde transport of Golgi enzymes that may have escaped their resident cisternae also occurs in COPI‐coated vesicles. At the distal face of the Golgi the TGN ensures the correct targeting of proteins, either constitutively or regulated to the plasma membrane, or to intracellular membrane compartments such as proteolytic or secretory lysosomes.

Controversy exists regarding the mechanism for anterograde movement of cargo proteins within the Golgi apparatus. The Golgi apparatus contains secretory proteins that can vary in physical size, from relatively small polypeptides to large, bulky multisubunit complexes; all need to reach the TGN for final sorting into transport intermediates. There are also resident glycosylation enzymes that have spatially restricted functions within the Golgi, that is, enzymes that function within specific subcompartments to ensure the correct addition or trimming of N‐ and O‐linked sugars on secreted proteins as they progress through the pathway. This raises a key question: how do protein and lipid cargo move through the Golgi apparatus while resident enzymes retain their localization? We know that many Golgi enzymes contain transmembrane Golgi localization signals that mediate targeting to a specific compartment ([@bib0239]). Two models have been proposed: the cisternal maturation model and the vesicular transport model ([@bib0093], [@bib0340]). Briefly, the cisternal maturation model suggests that large proteins or aggregates remain within a single Golgi cisterna, which matures through the retrograde transfer of resident enzymes via COPI vesicles. In contrast, the vesicular transport model proposes that newly synthesized protein is trafficked from cisterna to cisterna via COPI‐coated vesicles that sequentially bud off membranes and fuse with the next subcompartment. In either case, COPI‐coated vesicles play a central role in intra‐Golgi transport. A number of SNARE proteins, such as membrin, rbet1, GS27, and syntaxin‐5, have also been localized to the Golgi apparatus and are required for intra‐Golgi transport and homeostasis ([@bib0248]).

Golgi‐tethering molecules called golgins and Golgi reassembly stacking proteins (GRASPs) belong to a family of regulatory factors involved in Golgi maintenance and vesicular transport. The reader is pointed to an in‐depth review that covers golgins in more detail ([@bib0323]). In brief, the golgins can be anchored to Golgi membranes through various mechanisms and contain characteristic coiled‐coil domains that extend from the membranes as a rod‐like structure ([@bib0036]). Golgins such as giantin and golgin‐84 are securely anchored to the membrane via a transmembrane domain near their C terminus. Electrostatic or ionic interactions mediate the attachment of other golgins to membranes. For example, proteins of the GRASP family (GRASP65 and GRASP55) bind to GM130 and golgin‐45 to recruit these factors to the *cis* and *medial* Golgi membranes, respectively. Moreover, a large number of golgins are recruited to membranes via interactions with the Rab, ARF, and ARL (ARF‐like) GTPases. Vesicular and *cis*‐Golgi membrane recruitment of golgin p115 is regulated by Rab1, whereas membrane attachment of yeast golgin Rud3p is regulated by ARF1p. Golgin‐97 binds to membranes by interaction with ARL1p, a member of a new class of ARF‐like GTPases termed ARLs ([@bib0323]). Interestingly, autoantibodies directed against giantin, golgin‐245, golgin‐160, GM130, and golgin‐97 golgins and GRASPs are present in patients with autoimmune conditions such as Sjögren\'s syndrome and systemic lupus erythematosus.

In Sjögren\'s syndrome, moisture‐producing glands are targeted by the autoimmune response, resulting in dry eyes and mouth ([@bib0198]). Systemic lupus erythematosus is a chronic rheumatic condition that affects joints and muscles, causing skin rash and kidney problems. Sjögren\'s syndrome patients can also simultaneously display both rheumatoid arthritis and systemic lupus erythematosus.

Golgi biogenesis requires golgin function at different stages during cell division. Mammalian p115 is crucial for maintenance of the stacked nature of the Golgi cisternae ([@bib0282]). During mitosis, the Golgi stack disperses into clustered vesicles. These vesicles then fuse in the daughter cells to form new cisternae, alignment and stacking of which result in the formation of a fully functional organelle. GRASP65 tethers have been proposed to hold cisternae in close proximity through interactions with p115 and GM130 ([@bib0324]). The golgin p115 is also involved in tethering COPI vesicles to Golgi membranes ([@bib0330]) and may be needed for SNARE complex assembly ([@bib0325]). The budding yeast p115 homolog (Uso1p) tethers COPII‐coated vesicles to Golgi membranes during anterograde transport from ER exit sites to the *cis*‐Golgi ([@bib0011], [@bib0041], [@bib0300]). Mammalian p115 is also essential for the tethering of transport vesicles to the *cis*‐Golgi ([@bib0004]) and during intra‐Golgi transport ([@bib0316], [@bib0373]).

Golgins such as golgin‐84 are implicated in the regulation of Golgi structure and the formation of the Golgi ribbon ([@bib0079]). Golgin‐97 may function as a tethering molecule in retrograde traffic from the endosome to the TGN ([@bib0208]). Moreover golgins are also implicated as tethering components between the cytoskeleton and the Golgi apparatus ([@bib0323]).

B. Late Secretory Pathway: Post‐TGN Trafficking {#sec0009}
-----------------------------------------------

The *trans*‐Golgi network (TGN) is the final Golgi subcompartment where secreted proteins are sorted, packaged, and directed to their final destination. Trafficking from the TGN can occur in either a constitutive or regulated manner. Constitutive transport is the continuous release of protein from the *trans*‐Golgi network. Regulated secretion occurs in response to extracellular stimuli such as secretagogues, metal ions, hormones, or growth factors, which trigger the docking and fusion of secretory granules or vesicles with the plasma membrane.

Various mechanisms control the trafficking of proteins from the TGN by the formation and delivery of membrane‐derived transport vesicles to the plasma membrane, endosomes, or lysosomal structures ([@bib0279]). The expression of inactive (dominant‐negative) protein kinase D isoforms in tumor lines ([@bib0199]), polarized canine kidney cells ([@bib0394]), and mouse fibroblasts ([@bib0281]) has been shown to inhibit vesicle fission (release) from the TGN. Vesicle release is modulated by this family of kinases in response to cellular diacylglycerol ([@bib0014]) and binding to an as yet unknown effector protein on the cytoplasmic face of the TGN ([@bib0367]). In addition, the Cdc42 GTPase is linked to actin remodeling and has been shown to inhibit the exit of basolateral targeted proteins in polarized cells ([@bib0175], [@bib0242]) and copper‐regulated protein transport ([@bib0054]).

Copper is an essential element and cofactor required for functionality of many secreted enzymes (cuproenzymes). At steady state, ATP7A (Menkes disease copper transporter; [Section III.A.1](#sec0005){ref-type="sec"}) resides in the TGN, where it provides newly synthesized cuproenzymes such as lysyl oxidase with copper ions as they traverse the secretory pathway. When intracellular copper ion levels rise, ATP7A responds to this environmental danger by redistributing to the plasma membrane in a Cdc42‐regulated manner ([@bib0054]). Here, ATP7A acts as a copper efflux pump to remove copper ions from the cytoplasm to maintain homeostatic function and prevent toxicity. When copper levels are reduced, ATP7A recycles back to the TGN. This endocytic internalization and sorting event is independent of both clathrin and caveolae ([@bib0055]), although relying on a cytoplasmic dileucine motif present in the ATP7A C--terminus ([@bib0108], [@bib0275]).

Dent\'s disease, an X‐linked kidney disorder that presents with hypercalciuria, nephrocalcinosis (kidney stone formation), and progressive renal failure, is caused by missense, nonsense, and deletion mutations within the endosomal CLC‐5 voltage‐gated chloride channel. CLC‐5 is a member of a large family of voltage‐gated chloride channels that have a diverse array of cellular functions including membrane excitability, transepithelial ion transport, and cell volume regulation ([@bib0357]). When expressed in *Xenopus* oocytes, a number of missense mutations in the CLC‐5 gene localized the channel to the Golgi apparatus and showed reduced conductance and significantly reduced plasma membrane (PM) localization ([@bib0209]). Similarly, expression of mutant CLC‐5 alleles in cultured cells revealed an approximate 5‐fold increase in Golgi retention ([@bib0042]).

IV. Internalization and Recycling {#sec0010}
=================================

A. Receptor‐Mediated Endocytosis {#sec0011}
--------------------------------

### 1. Clathrin‐Coated Vesicles {#sec0012}

Clathrin‐coated vesicles (CCVs) are a route for protein internalization conserved from yeast to humans. [@bib0292] first observed this process in mosquito oocytes and these vesicles have subsequently become one of the best characterized membrane transport steps in eukaryotes. Clathrin is one of the principal proteins involved in this transport step and, in combination with more than 25 clathrin‐associated factors, this unique structural component forms transport vesicles on the cytoplasmic face of the TGN, endosomes, and the plasma membrane. Clathrin‐coated vesicles bud from their donor membranes and are directed to target membranes by associated proteins and factors.

This highly conserved 600‐kDa clathrin complex comprises heavy (180 kDa) and light (25 kDa) chain proteins that are assembled into a three‐legged structure called a triskelion. Triskelions can be polymerized by accessory factors into striking lattice‐like "cages" comprising pentagons and hexagons, resembling a soccer ball structure or buckminsterfullerene. Clathrin cages are ∼70--120 nm in diameter; significantly larger than COPI or COPII vesicles (CCVs).

Clathrin‐coated vesicles are believed to assemble through a sequence of events that can be designated as activation, cargo capture, coat assembly, scission, movement, and vesicle uncoating ([@bib0164]). Members of a class of clathrin‐associated factor termed adaptor protein (AP) complexes are recruited to donor membranes through interactions with a docking complex, which then further interacts with motifs within the cytoplasmic tail of cargo proteins, resulting in "cargo capture." This leads to clathrin cage assembly and the concomitant polymerization of the clathrin triskelion and resultant deformation of the donor membrane. Scission, or vesicle release from the plasma membrane, is believed to occur through the action of the GTPase dynamin and other accessory proteins, such as amphiphysin ([@bib0378]). In the fruit fly *Drosophila melanogaster*, a dynamin gene mutation (*shibire*) causes temperature‐sensitive paralysis. This is likely due to a block in the endocytic uptake of synaptic vesicle proteins at the plasma membrane, leading to a block in recycling and reformation of competent synaptic vesicles at nerve terminals ([@bib0047], [@bib0170], [@bib0171], [@bib0365]). The expression of a dominant‐negative GDP‐bound dynamin mutant, K44A, results in compromised CCV formation ([@bib0137], [@bib0366]) and inhibition of clathrin‐mediated internalization of the glucose transporter GLUT4 ([@bib0002]), human immunodeficiency virus (HIV) ([@bib0063]), and influenza virus ([@bib0296]). The scission function of dynamin is assisted by specific lipid‐modifying enzymes such as endophilin, synaptojanin, and phospholipase D ([@bib0023], [@bib0127], [@bib0288], [@bib0306], [@bib0383]). Finally, CCV uncoating at the target membrane occurs through the actions of the heat shock protein Hsc70 ([@bib0305]) and auxilin ([@bib0362]).

Sorting of proteins from donor to target membranes involves the recognition of cytoplasmic sequences in membrane proteins by clathrin‐associated AP complexes. Four adaptor protein complexes (AP1--AP4), each comprising four different subunits, have been identified ([@bib0290]). The AP1 complex is involved in clathrin‐coated vesicle formation at the TGN for transport to late endosomes; evidence has also implicated a role for this complex in a TGN‐to‐plasma membrane step ([@bib0105]). AP2 is the best‐studied of the four complexes and mediates internalization of transmembrane receptors at the plasma membrane via clathrin‐coated vesicles. The AP3 complex is involved in trafficking from early endosomes to either late endosomes or lysosome‐related organelles such as melanosomes, platelet‐dense bodies, and antigen‐processing compartments. Finally, the AP4 complex was the last to be cloned ([@bib0138], [@bib0072]). In contrast to AP1--AP3, AP4 does not possess the β "ear" domain (see below), which allows interaction with clathrin and other cytosolic factors such as Eps15 and auxilin 2 ([@bib0211]). By electron microscopy, AP4 has been localized to vesicles at the TGN, plasma membrane, and early endosomes, although there is debate as to whether these vesicles are clathrin‐coated ([@bib0138], [@bib0013]). Interestingly, AP3 and AP4 may function independently of clathrin ([@bib0138], [@bib0369]), suggesting the existence of another, as yet unidentified, coat protein that is analogous to clathrin.

All four AP complexes comprise two large 100‐kDa subunits: a β subunit (β1--β4) plus a γ (AP1), α (AP2), δ (AP3), or ε (AP4) subunit. In addition, each AP complex contains a 50‐kDa subunit (μ1--μ4) and a small 20‐kDa subunit (σ1--σ4). AP1, ‐2, and ‐3 contain two carboxyl "ear" domains connected to the head of each large 100‐kDa subunit by a flexible hinge of approximately 20--30 residues. Importantly, the ear domain of the β subunit and the hinge domains of the γ and α subunits have been shown to bind clathrin ([@bib0119], [@bib0236], [@bib0260]), and consensus sequences in the hinge domains of β1 and β2 have clathrin‐binding properties ([@bib0071]).

The β and μ subunits of the AP complex interact with motifs present in the cytoplasmic domains of transmembrane proteins to mediate cargo recruitment into clathrin‐coated vesicles. Such motifs include NPXY, YXXØ, and dileucine‐based sequences (Ø represents a bulky hydrophobic amino acid). One such motif, NPXY, is present in key cellular receptors such as low density lipoprotein receptor (LDLR), epidermal growth factor receptor (EGFR or Erb1), and insulin receptor, and mediates endocytosis and sorting. Importantly, the JD mutation (Y807C) in LDLR lies within this key motif and causes familial hypercholesterolemia ([@bib0167]). The second tyrosine‐based motif, YXXØ, mediates plasma membrane internalization, lysosomal targeting, and basolateral targeting of cargo. This motif is found in lysosomal residents such as LAMP‐1 and ‐2, CD63, the recycling transferrin receptor (TfR), and TGN‐associated recycling membrane proteins, furin and TGN38. Di‐leucine motifs present on transmembrane transporters such as GLUT4 (glucose transporter), ATP7A, and mannose‐6‐phosphate receptors (M6PR) can fall into two categories: \[DE\]XXX\[LI\] and DXXLL related motifs. The \[DE\]XXX\[LI\] motif is associated with proteins internalized from the plasma membrane and targeted to lysosomes, while DXXLL motif is found in transmembrane proteins that shuttle between the TGN and endosomal system ([@bib0029]).

Another class of clathrin‐associated factor is the *G*olgi‐localized, γ‐ear‐containing, *A*RF‐binding proteins (GGAs) found on the TGN and postulated to interact with AP1 to mediate transport of M6PR ([Section V.B](#sec0018){ref-type="sec"}) to endosomes ([@bib0082]). GGAs can act as multifunctional adaptors that link transmembrane proteins, ARF GTPases, clathrin and accessory proteins at sites of CCV formation ([@bib9003]).

The disease oculocerebrorenal syndrome of Lowe (OCRL) is an X‐linked disorder caused by mutations in the *OCRL1* gene ([@bib0207]). The gene product is an inositol 5′‐phosphatase that catalyzes the removal of the phosphate from this position on the inositol moiety. The preferred OCRL1 substrate is PI(4,5)P~2~, a phosphoinositide shown to be important in endocytosis because of its central role in recruiting accessory proteins to CCVs ([@bib0261]). OCRL1 has been localized to clathrin‐coated vesicles associated with endosomal and TGN membranes ([@bib0049]). This is not surprising as OCRL1 interacts with clathrin and promotes its assembly into clathrin lattices and cages ([@bib0049], [@bib0363]). OCRL1 also interacts with the Rac1 GTPase that regulates actin dynamics, possibly via a GTPase activation domain to accelerate GTP hydrolysis ([@bib0098]). Although the exact function of OCRL1 is still unclear, the disease phenotype hints to OCRL1 function in membrane trafficking. OCRL1 mutations can cause loss of protein expression and phosphatase activity. RNAi‐mediated inhibition of OCRL1 expression in cultured human cells results in partial redistribution of a cation‐independent mannose‐6‐phosphate receptor and a TGN recycling protein (TGN46) to early endosomes ([@bib0049]). This suggests that loss of OCRL1 perturbs endosome‐to‐TGN vesicle transport, suggesting a functional requirement for this membrane traffic step. It is possible that OCRL1 plays a role in anterograde trafficking from the TGN‐to‐endosomes as well, since OCRL1 is abundantly present on TGN‐associated clathrin buds destined for the endocytic pathway.

OCRL disease symptoms include congenital cataracts, mental retardation, and renal tubular dysfunction ([@bib0206]). Renal failure in OCRL patients is probably partly caused by defects in solute and protein re‐adsorption in kidney proximal tubules. This is likely due to missorting of megalin and cubilin, cell surface receptors involved in kidney solute uptake. In OCRL1 patients plasma membrane shedding of these receptors is reduced ([@bib0251]), indicating OCRL1 regulation of either receptor trafficking from the TGN‐to‐plasma membrane or recycling from plasma membrane‐to‐TGN.

Paraneoplastic stiff‐person syndrome (SPS) is a neurological autoimmune disease characterized by severe muscle stiffness and spasms, and often has secondary symptoms including diabetes, epilepsy, and breast cancer. Autoantibodies are produced against the clathrin‐associated regulator, amphiphysin I ([@bib0067]), a protein shown to bind dynamin in nerve terminals ([@bib0066]) and which is implicated in regulating the endocytosis of neuronal synaptic vesicle components ([@bib0038]). In support of this hypothesis, [@bib0329] showed that SPS‐like symptoms could be triggered in rats injected with anti‐amphiphysin antibodies from a human SPS patient.

Genetic translocations leading to the formation of hybrid clathrin‐accessory proteins can lead to other forms of acute myeloid leukemia, lymphoblastic leukemia and acute megakaryoblastic leukemia ([@bib0084], [@bib0154], [@bib0244], [@bib0355]). In these diseases, an aberrant hybrid protein consisting of the putative transcription factor AF10 and the clathrin accessory protein CALM (*c*lathrin *a*ssembly *l*ymphoid *m*yeloid leukemia protein) is formed because of a partial inversion of the AF10 gene on chromosome 11 ([@bib0299]).

Finally, in Hermansky‐Pudlak syndrome (HPS) type 2, a condition that results in partial albinism and prolonged bleeding, mutations have been found in the β3A gene that encodes a subunit of the AP3 adaptor complex ([@bib0073]). HPS is discussed in more detail in [Section V.C](#sec0019){ref-type="sec"}.

B. Alternative Internalization Routes {#sec0013}
-------------------------------------

### 1. Caveolae {#sec0014}

Originally identified more than 50 years ago ([@bib0262], [@bib0387]), caveolae are flask‐shaped invaginations of approximately 50--100 nm in diameter at the plasma membrane. These plasma membrane profiles are related to lipid rafts and contain unique mixtures of GPI‐anchored proteins, transmembrane proteins, signaling factors and lipids, such as cholesterol. Caveolae are believed to mediate the uptake of small solutes, regulate protein trafficking ([@bib0142], [@bib0346]), transcytosis (transport across endothelial cells) ([@bib0326]), signal transduction ([@bib0149], [@bib0201], [@bib0259]) and cholesterol homeostasis ([@bib0102]). However, their exact role in the internalization of membrane proteins and soluble protein ligands is controversial.

Caveolin‐1, also known as VIP21, is a structural component essential for the formation and stability of caveolae ([@bib0180], [@bib0293]). Of the three members of the caveolin gene family (caveolin‐1, ‐2, and ‐3) ([@bib0304], [@bib0351]), caveolin‐1 and ‐2 are abundant in a wide variety of cell types including endothelial cells, adipocytes, alveolar type I pneumocytes, and smooth muscle cells ([@bib0379]), whereas caveolin‐3 is a muscle‐specific isoform expressed in striated muscle cells such as cardiac and skeletal myocytes ([@bib0057], [@bib0351]). Caveolin‐1 and ‐3 are both able to induce formation of caveolae at the plasma membrane ([@bib0112], [@bib0194]). However, caveolin‐2 requires the presence of caveolin‐1 for expression, membrane localization, and formation of caveolae ([@bib0285]).

Caveolae are absent from cells that lack caveolin‐1 but can be induced by ectopic expression of the gene ([@bib0107]). Caveolins adopt a hairpin‐like structure that inserts into the membrane such that the N and C termini are cytoplasmic. Caveolins can polymerize to form a striated coat surrounding an invagination site ([@bib0268]). Caveolin‐1 can bind cholesterol ([@bib0240]), which is enriched within both caveolae and lipid rafts ([@bib0301]); this may explain why caveolae have been considered a subset of lipid rafts. However, caveolae and lipid rafts are considered to be independent entities as some proteins can be found in one but not the other ([@bib0202]). Certain ligands can internalize via a lipid raft‐dependent but clathrin‐independent mechanism in cells that lack caveolae ([@bib0183]).

A large pool of the plasma membrane caveolar vesicles cluster into dense grape‐like structures where individual caveolae appear stacked on top of each another ([@bib0358]). These structures are intimately associated with the actin cytoskeleton ([@bib0333]); caveola‐associated proteins are also implicated in regulating plasma membrane dynamics and cellular movement. A small pool of "transport‐competent" caveolar vesicles may undergo short‐range constitutive fusion and budding cycles just under the plasma membrane ([@bib0268]). Caveolae and caveolins can also be detected at the TGN ([@bib0089], [@bib0180]) and may form stable "platforms" for the movement of proteins and lipids from the TGN to the plasma membrane ([@bib0346]).

The caveolar pathway can be hijacked and used by pathogens or toxins to gain entry into the cell. Viruses such as polyomavirus, echovirus 1, and simian virus 40 (SV40) use caveolae to internalize viral particles. These viruses cluster lipid rafts and sequester them into caveolae through interactions with raft components such as integrins and glycosphingolipids ([@bib0268]); in the case of SV40, the virus binds to the raft component ganglioside GM~1~ ([@bib0360]). [@bib0346] have shown that SV40 can trigger the long‐range movement of transport‐competent caveolar vesicles. Moreover, cell infection with SV40 more than doubles the number of caveolae capable of undergoing viral internalization and long‐range trafficking.

Caveolae contain much of the molecular machinery required for "classical" vesicle fission, docking, and fusion, for example, SNARE proteins, monomeric and trimeric GTPases, annexins II and VI, *N*‐ethylmaleimide (NEM)‐sensitive fusion protein (NSF), and ATPases ([@bib0308]). Caveolae also contain the dynamin GTPases, which can be transiently recruited to SV40‐loaded caveolae and implicated in membrane scission ([@bib0135], [@bib0256], [@bib0269]). Internalized caveola‐derived vesicles move to an endocytic compartment termed the "caveosome" and eventually arrive at the early endosome. After fusion with the target compartment, caveolae do not disassemble but maintain their integrity in the membrane, preserving their compartmentalization and retaining their lipid and protein components ([@bib0271]). The fate of internalized SV40 viruses after reaching the caveosome eventually results in arrival at the smooth ER ([@bib0270]).

Interestingly, mutations in caveolin have been implicated in muscular dystrophy and cardiovascular disease, and mutations causing the downregulation of caveolin have been linked to the progression of various human carcinomas; it is therefore possible that caveolins may have a tumor suppressor role. The caveolin‐1 and caveolin‐2 genes are located on human 7q31.1 near the microsatellite repeat marker D7S522. This region is commonly deleted in various cancers ([@bib0095]), hinting that caveolin gene deletion may be advantageous for tumor progression. In one report, the caveolin‐1 P132L mutation was present in 16% of breast cancer patients studied ([@bib0131]). The P132L mutation was also linked to the metastatic potential of tumors and disease prognosis. The caveolin‐1 P132L mutation also conferred increased cell migration and altered morphology. Caveolin‐1 protein levels can be reduced or absent from a number of human breast cancer cell lines compared with normal mammary cells ([@bib0186]). Similarly, silent and missense mutations in caveolin‐1 have also been associated with oral carcinomas ([@bib0128]). Caveolin‐1, and to a lesser extent caveolin‐2, gene expression is downregulated in some cases of thyroid carcinoma ([@bib0001]).

Although it remains unclear as to why the loss of caveolin causes cell proliferation diseases such as cancer, one can speculate on the role of caveolin in regulating signaling pathways. In endothelial cells, which have a high abundance of caveolin, the key vascular endothelial growth factor receptor 2 (VEGFR2) has been shown to be inactive when localized to caveolae ([@bib0181]). This receptor tyrosine kinase modulates the endothelial response to the key VEGF‐A cytokine and controls angiogenesis and new blood vessel formation, thus regulating neovascularization and tumor growth ([@bib0246]). Similarly, platelet‐derived growth factor (PDGF) receptor tyrosine kinase activity is reduced when associated with caveolae ([@bib0388]). In addition to VEGFR2 and PDGFR, a number of G protein‐coupled receptors (GPCRs) have been shown to interact with caveola‐associated factors ([@bib0149]). GPCRs are a large family of transmembrane receptors involved in a variety of signal transduction events. These receptors are activated by a range of ligands, including hormones and peptides, and have been linked to a number of cancers such as thyroid, lung, and gastric. The presence of a number of GPCRs in caveolae suggests that these plasma membrane structures may interact with GPCRs and modulate their signaling potential. Lisanti and others ([@bib0193]) have shown that caveolin‐1 interacts solely with inactive forms of G‐protein α subunits, lending credence to the negative regulation hypothesis caused by the association of caveolae with transmembrane signaling receptors.

A number of mutations in muscle‐specific caveolin‐3 have been associated with four distinct but related autosomal dominant muscle disease phenotypes ([@bib0382]): limb girdle muscular dystrophy type 1c ([@bib0229]), rippling muscle disease, hyperCKemia (persistently elevated levels of serum creatine kinase), and distal myopathy. Some mutations cause aberrant retention of caveolin‐3 in the Golgi and subsequent degradation; other mutations may cause mutant caveolin‐3 to act in a dominant‐negative manner by forming unstable aggregates with wild‐type caveolin‐3 ([@bib0111], [@bib0331], [@bib0332]). Hypertrophic cardiomyopathy (HCM) patients have a caveolin‐3 T63S mutation that reduces plasma membrane levels ([@bib0132]).

Caveolin gene knockout mice are providing insights into protein function in different human diseases. For example, lack of caveolins can cause diabetes, atherosclerosis, and cardiomyopathies in mouse models ([@bib0057], [@bib0379]). However, such phenotypes have yet to be linked to caveolin dysfunction in humans.

### 2. Phagocytosis {#sec0015}

Phagocytosis is a process used by white blood cells such as macrophages, neutrophils, and dendrites to ingest large particulate material into specialized vesicles called phagosomes. These professional phagocytes are paramount in the defense against infection as they engulf and ingest whole microorganisms such as bacteria. They also use this route for "mopping up" apoptotic debris or senescent cells from tissues. In contrast to constitutive pinocytic transport, phagocytosis is regulated by cell surface‐localized Fc receptor (FcR) contact or interaction with complement‐ or antibody‐coated particles which results in clustering of FcR on the cell surface, a step important for subsequent intracellular signaling and cellular activation ([@bib0064]).

Polymorphisms in leukocyte‐specific Fcγ receptors may contribute to autoimmune diseases such as Guillain‐Barré syndrome or rheumatoid arthritis, and enhanced susceptibility to infection ([@bib0368]). Fc‐mediated binding can trigger a complex signaling response involving extrusion of fine plasma membrane projections (pseudopodia) from the macrophage to surround and engulf the pathogen, forming a phagosome. The signaling response is reviewed in greater detail elsewhere ([@bib0028], [@bib0048], [@bib0250]). In brief, the activation of tyrosine kinases and Rho GTPases is triggered through FcR signaling. The Rac and Cdc42 GTPases, in conjunction with the downstream effector WASP, mediate remodeling of the actin cytoskeleton, leading to pseudopodium formation and phagosome closure ([@bib0044], [@bib0048]). In contrast, the complement mediated‐uptake of opsonized particles differs such that they appear to "fall" into the cell in a process that requires Rho, but not Rac or Cdc42 ([@bib0028]).

Phagocytosis, although designed to destroy pathogens, can paradoxically be used as a route of entry by pathogens such as *Mycobacterium* (*M. leprae* and *M. tuberculosis*) or *Leishmania* ([@bib0247], [@bib0313]). Normally, internalized pathogens are destroyed successfully through phagosome maturation into lysosomes and subsequent degradation. *Mycobacterium* can evade host degradation by secreting a soluble serine/threonine protein kinase G molecule into the phagosome. This molecule initiates a signaling response that interferes with phagosome--lysosome fusion, and promotes intracellular pathogen survival ([@bib0370]). Furthermore, phagosome maturation is compromised by a pathogen induced block of p38 MAP (mitogen‐activated protein) kinase recruitment to the tethering molecule early endosome antigen 1 ([@bib0110]).

The *Leishmania* protozoan parasite, which is transmitted to humans by sand flies, produces a membrane molecule called a lipophosphoglycan, which is inserted into the lipid bilayer of the phagosome in infected macrophages. This lipophosphoglycan is thought to modulate intracellular signaling pathways, resulting in a less fusogenic phagosome and preventing maturation; this would facilitate pathogen replication and disease progression ([@bib0204]).

V. Protein Trafficking Through the Endosomal--Lysosomal System {#sec0016}
==============================================================

A. Endosomal Sorting and Recycling {#sec0017}
----------------------------------

Molecules internalized from the cell surface by receptor‐mediated endocytosis and clathrin‐coated vesicles are delivered to the early endosome for sorting. Molecules such as low‐density lipoprotein receptor (LDLR) and transferrin receptor (TfR) are efficiently recycled between the early endosome and the plasma membrane. However, after ligand‐mediated activation ([Fig. 3](#fig0003){ref-type="fig"} ), receptor tyrosine kinases such as epidermal growth factor receptor (EGFR) are sorted along the endocytic pathway for degradation.Fig. 3Protein trafficking through the endosomal--lysosomal system. Cell surface receptors are internalized through clathrin‐coated vesicles (CCVs) at the plasma membrane. In the cell cytoplasm, CCVs shed their coat components and fuse to produce endosomes. Internalized receptors are either recycled from sorting endosomes (housekeeping receptors, e.g., transferrin receptor) or targeted for degradation within the lysosome (signaling receptors, e.g., growth factor receptors) after movement through the late endosome and multivesicular body (MVB) compartments.

Early endosomes are thought to be formed through the fusion of internalized vesicles and recruitment of specific proteins and lipids. One key endosomal regulator is the ubiquitously expressed Rab5a GTPase. Rab5a is present on the cytosolic face of the plasma membrane, vesicles, and tubular endosomal profiles ([@bib0046]). A number of Rab5a‐associated effector proteins regulate endosomal fusion and mediate protein cargo movement and endosomal sorting ([@bib0397]). Such effector proteins, including Rabaptin‐5, Rabex‐5, and Rabenosyn‐5, are clustered on the cytosolic face of the early endosome and stabilize the GTP‐bound Rab5a in an activated state ([@bib0144]). GTP‐bound Rab5a directly binds to early endosome antigen EEA1 to regulate vesicular and endosomal tethering. EEA1 contains a C‐terminal Rab5a‐binding domain, and a phosphatidylinositol 3‐phosphate‐binding zinc finger domain referred to as an FYVE (conserved in *F*ab1, *Y*OTB, *V*ac1, and *E*EA1) domain ([@bib0115], [@bib0334]). Overexpression of wild‐type Rab5a, or a constitutively active Rab5a mutant, causes endosome enlargement and defective trafficking through this compartment, whereas expression of a constitutively inactive Rab5a mutant leads to formation of small endosomes and decreased endocytosis ([@bib0033]). A family of effector proteins that accelerate GTPase hydrolysis (RabGAPs) have been identified: RabGAP‐5 binds to Rab5a and regulates trafficking through the endocytic pathway ([@bib0125]).

The importance of Rab5a activity is further illustrated in the genetic disorder tuberous sclerosis (TS), a disease that causes tumors in the brain, eyes, heart, kidneys, lungs, and skin. TS arises when the tumor suppressor gene, tuberous sclerosis complex (TSC), is absent; introduction of the wild‐type TSC2 gene into an animal model or cultured cells results in tumor suppression and reduced cellular proliferation ([@bib0169], [@bib0395]). Interestingly, the TSC2 gene product (tuberin) is implicated in regulating GTP/GDP exchange on Rab5a, thus regulating trafficking through this endosome system ([@bib0386]). In chronic myelomonocytic leukemia (CMML) a genetic translocation causes fusion of Rab5a effector Rabaptin‐5 and the PDGFβR ([@bib0214]). This chromosomal translocation results in enhanced cellular proliferation by compromising endosomal fusion and trafficking, and thus regulation of growth factor degradation. It is likely that this aberrant gene product is not degraded and triggers sustained intracellular signaling, leading to cell proliferation and tumor progression in a subset of lymphoid cells.

Recycling from endosomes back to the cell surface is often used by receptors that internalize nutrients such as lipoproteins and ions. Receptor recycling rather than degradation conserves receptor functionality and nutrient uptake and reduces energy expenditure in the synthesis of new receptors ([@bib0238]). Genetic screens in the nematode *Caenorhabditis elegans* identified RME‐1 and delineated a new family of conserved class of Eps15 homology (EH) domain proteins ([@bib0122]). Both the worm and mouse homologs of RME‐1 are associated with the endosomal compartment: a dominant‐negative RME‐1 G429R mutant had little effect on receptor‐mediated endocytosis but had a substantial effect on endosomal recycling, suggesting a functional role in this step ([@bib0200]).

Although information is currently limited, a number of neurological diseases are associated with dysfunction of early endosomal proteins. In some cases of demyelinating polyneuropathy, characterized by progressive weakening and sensory dysfunction of the legs and arms, EEA1 autoantibodies have been detected ([@bib0317]). A number of disorders, from muscular dystrophy to rheumatoid arthritis, reveal the presence of circulating anti‐EEA1 antibodies. Interestingly, EEA1 epitopes recognized by such autoantibodies varied from patient to patient ([@bib0318]). Autoantibodies against EEA1 have also been detected in cases of subacute cutaneous systemic lupus erythematosus (SCLE), characterized by the appearance of an unsightly red rash, often occurring after sun exposure ([@bib0237]).

B. Lysosomal Sorting and Protein Degradation {#sec0018}
--------------------------------------------

Lysosomes are terminal, membrane‐enclosed degradative compartments that interact with other organelles through vesicular transport originating from the secretory, endocytic, and autophagic pathways. This organelle stores various proteases, lipases, hydrolases, and degradative enzymes within an acidic environment that maximizes enzymatic activity and degradation. Resident lysosomal membrane proteins, integral proteins, and glycoproteins are targeted to the organelle via the endosome. Lysosomal proteases such as cathepsin D are processed in the Golgi apparatus to add a mannose 6‐phosphate (M6P) moiety to N‐linked sugars. The M6P moiety is recognized by plasma membrane or TGN‐resident mannose 6‐phosphate receptors (M6PRs) and sorted to the late endosome and eventually the lysosome. Here, the acidic pH (pH \< 5.5) results in receptor--ligand disassociation and recycling of the M6PR to the TGN. Fusion between the endosome and preexisting primary lysosomes allows the delivery of lysosomal resident proteins.

The importance of M6P‐mediated targeting of lysosomal proteins is highlighted in the human neurological disorder, I‐cell disease (mucolipidosis II), where lysosomal enzymes are secreted from cells rather than targeted to the lysosome. The defect in I‐cell disease involves lack of M6P moiety addition as a result of mutations to the N‐acetylglucosamine‐1‐phosphotransferase enzyme usually present within the Golgi apparatus ([@bib0020]).

How lysosomes are formed is still unclear ([@bib0213]). Three mechanisms have been proposed to explain lysosomal biogenesis: vesicular transport between late endosomes and preformed primary lysosomes ([@bib0123]), early endosomal "maturation" to lysosomes ([@bib0241]), or the current favored model of "kiss‐and‐run," in which transient interactions between endosomes and lysosomes transfer endosomal contents to the latter compartment ([@bib0085], [@bib0339]). Late endosome and lysosome interactions in the kiss‐and‐run model are thought to be regulated by the Rab7 GTPase, which is present on late endosomes; a Vps complex, homologous to budding yeast vacuole fusion regulators, is also implicated in sorting and delivery to lysosomes ([@bib0315]). The mammalian form of the Vps complex interacts with syntaxin‐7, a t‐SNARE that is concerned in regulating membrane dynamics along this route ([@bib0162]).

Danon disease is caused by point mutations in, or complete absence of lysosome‐associated membrane protein 2 (LAMP2) or complete absence of this protein: changes which result in cardiomyopathy, myopathy, and mental retardation. In Danon disease patients and LAMP2‐deficient mice, autophagic vacuoles accumulate within the cytoplasm; these vacuoles arise via intracellular engulfment of old membranes to form an autophagosome, thus sequestering membranes and proteins for eventual degradation ([@bib0322]). Autophagosomes fuse with lysosomes, leading to degradation for provision of molecules for cellular homeostasis. The accumulation of autophagic vacuoles in LAMP2‐deficient cells suggests that LAMP2 mediates interactions between autophagosomes and lysosomes. This pathway is commonly activated during conditions of cellular stress such as starvation or pathogenic infection ([@bib0165]).

Lysosomal storage diseases are caused through insufficient degradation of targeted components within lysosomes, leading to substrate accumulation and lysosome enlargement. More than 40 lysosomal storage diseases have been documented and generally manifest themselves as neurological disorders; disease severity correlates with the levels of lysosomal enzyme activity. Niemann‐Pick disease is a neurodegenerative condition caused by sphingomyelin accumulation in reticuloendothelial cells and ganglion neurons, leading to cell death. It is classified into five types (A--E), each distinguished by either clinical severity or age‐related disease phenotype. Niemann‐Pick type A (NPA) is most common, with death occurring before 3 years of age. NPA patients have point mutations in the SMPD1 gene that encodes a lysosomal sphingomyelinase ([@bib0190], [@bib0347]). Interestingly, in NPC patients, endocytosed LDL particles are not fully degraded in lysosomes, leading to defects in cholesterol metabolism ([@bib0191]). The NPC disease is caused by mutations in the NPC1 gene, which encodes a lysosomal resident protein with similarity to sterol‐sensing enzymes and proteins ([@bib0312]).

Fabry disease is an X‐linked condition caused by changes in lysosomal α‐galactosidase activity resulting in glycosphingolipid accumulation within vascular endothelial lysosomes. This leads to angiokeratomas (a wart‐like thickening of the skin), progressive renal impairment, cardiomyopathy, and cerebrovascular disease. Mutations in the α‐galactosidase A gene can also show reduced enzymatic activity of the encoded protein and retention within the endoplasmic reticulum ([@bib0393]).

Receptor tyrosine kinases such as epidermal growth factor receptor (EGFR) are degraded by lysosomes after ligand binding and receptor activation. EGFR lysosomal targeting is dependent on ligand‐stimulated ubiquitination of the cytoplasmic domain. Binding of EGF to EGFR causes downstream signaling, clathrin‐mediated internalization, and trafficking to endosomes. Internalized receptor--ligand complexes are sorted to the late endosome or multivesicular bodies (MVBs), which eventually deliver their contents to the lysosome ([@bib0158]). Whereas other receptors such as TfR are recycled to the plasma membrane, EGFR is moved through the endosome--lysosome system by a ubiquitin‐dependent sorting and recognition system. These include the Hrs/STAM heterodimer and TSG101 ([@bib0026]) present on endosomal membranes. The TSG101 tumor suppressor gene is mutated in nearly 50% of breast cancer patients and encodes a membrane‐associated protein ([@bib0185]). This factor participates in the sorting of ubiquitinated proteins on the endosome, but its exact function is not clear.

C. Secretory Lysosomes {#sec0019}
----------------------

In some specialized cells, such as cytotoxic T lymphocytes (CTLs), platelets, and melanocytes, regulated secretion can be routed through compartments other than the TGN. Such cells have evolved mechanisms whereby modified or secretory lysosomes release their contents at the plasma membrane in response to extracellular stimuli. These secretory lysosomes (SLs) share lysosomal characteristics such as acid pH and LAMP (lysosome‐associated membrane proteins) residents but also contain unique markers such as tyrosinase, present in melanosomes. The CTL secretory lysosomes contain unique components such as perforin and granzymes required for triggering apoptosis in target cells. On CTL contact with a target cell, SLs traffic toward the immunological synapse formed between the CTL and target cell. A signal then causes SL fusion with the CTL plasma membrane ([@bib0337]), and release of SL contents and subsequent target cell death.

A number of autosomal genetic diseases causing immunodeficiency and albinism involve defects in regulated lysosomal secretion ([@bib0338]). In the rare, fatal disease familial hemophagocytic lymphohistiocytosis (FHL) SLs congregate at the plasma membrane in CTLs, where they can dock but cannot fuse with the membrane. In one group of FHL patients, this disease is due to a mutation in the gene encoding Munc13‐4; this is closely related to the neuronal Munc13‐1 gene product that is involved in SNARE complex formation in neuronal cells ([@bib0100]). Assembly of this neuronal syntaxin‐1, SNAP‐25, and synaptobrevin complex is regulated by Munc18‐1, which binds and locks syntaxin‐1 (t‐SNARE) in a closed, inactive conformation, thus preventing it from interacting with SNAP‐25 ([@bib0390]). However, Munc13‐1 ([@bib0302]) and RIM (Rab3a‐interacting protein effector) ([@bib0172]) can compete with Munc18‐1 and displace it from syntaxin‐1. This reinforces the syntaxin‐1 open conformation and allows SNARE complex formation to occur. Munc13‐1 may act as a conformational switch to promote t‐SNARE into an "open" state, thus allowing formation of the SNARE complex that mediates synaptic vesicle docking and fusion. From observations of FHL patients, one speculation is that Munc13‐4 has a role similar to that of Munc13‐1 in regulating SNARE complex formation for SL docking and fusion in CTLs ([@bib0390]).

Chediak‐Higashi syndrome (CHS) is a key example of a disease affecting SL function in CTLs, with patients displaying hypopigmentation ([@bib0338]). CHS patients have genetic mutations in the Lyst or CHS1 gene ([@bib0010], [@bib0274]) and produce CTLs containing strikingly enlarged SLs that are able to polarize to the immunological synapse but are unable to fuse with the PM. This suggests a role for the CHS1 gene product in regulating membrane docking and fusion ([@bib0052], [@bib0053]). Overexpression of CHS1 leads to the presence of small lysosomes, indicating increased lysosomal fission ([@bib0372]). In addition, CHS1 interacts with SNARE proteins, further indicating a role in SL fusion ([@bib0354]).

Griscelli syndrome patients also display defects in SL dynamics within CTLs and exhibit hypopigmentation and silvery hair. In melanocytes, cells responsible for pigment storage and production, Rab27a is required to recruit melanophilin to pigment granules called melanosomes (SLs). Melanophilin binds the myosin motor protein myosin Va and regulates melanosome movement along actin cables to the plasma membrane ([@bib0148], [@bib0341], [@bib0385]). In type 1 Griscelli syndrome patients, Rab27a GTPase is missing or defective, whereas in type 2 Griscelli syndrome patients the myosin Va motor protein is absent. These defects are also evident in mouse models such as *ashen* (Rab27a defective), *dilate* (myosin Va defective), and *leaden* (melanophilin defective). In both the human Griscelli syndromes and the mouse models, melanosomes are clustered in a perinuclear location, a defect attributed to Rab27a dysfunction ([@bib0380], [@bib0384]). Interestingly, CTLs isolated from type 1 Griscelli syndrome patients and *ashen* mice (Rab27a deficient) are unable to kill target cells, whereas type 2 Griscelli syndrome patient and *dilate* mouse CTLs are functional. This suggests that Rab27a interacts with different effectors to induce SL fusion with the plasma membrane in different cell types ([@bib0126]).

Hermansky‐Pudlak syndrome (HPS) is a fourth example of SL dysfunction and is characterized by oculocutaneous albinism, ceroid deposition, and excessive prolonged bleeding ([@bib0136], [@bib0343]). However, HPS cannot be viewed as a single disease but a group of at least seven autosomal genetic disorders. Each of the seven subgroups (HPS1--7) is due to mutations in individual genes, most of which encode components of multisubunit protein complexes involved in vesicle trafficking ([@bib0195]), whereas the function of others remains unclear. Three of these complexes, termed BLOCs (*b*iogenesis of *l*ysosome‐related *o*rganelle *c*omplexes), play a role in regulating trafficking involved in platelet and melanosome secretion, but their exact functions are unclear ([@bib0080]). In HPS2 patients a nonsense mutation in the gene encoding the β3A subunit of the AP3 adaptor protein prevents expression of this subunit ([@bib0147]). As previously mentioned, AP3 is involved in the recruitment of transmembrane proteins into vesicles at the early endosome for delivery to the lysosome ([@bib0266]). In melanocytes derived from HPS2 patients, the tyrosinase that catalyzes the formation of melanin is not transported to maturing melanosomes ([@bib0146]). This leads to the characteristic pattern of albinism seen in patients with this condition.

Furthermore, patients with HPS2 display an impaired CTL response and immune response. CTLs from HPS2 patients have lytic granules that cannot move in an oriented fashion toward the microtubule‐organizing center; therefore, when CTLs are stimulated by contact with target cells, the lytic granules are not targeted to the immunological synapse for cell killing ([@bib0053]).

Studies on the cell biology of HIV infection have suggested the existence of a viral secretory compartment. Work by Marsh and others ([@bib0113], [@bib0173], [@bib0267]) has localized viral envelope (gp120) and matrix proteins (p17) to tetraspanin‐positive endosome‐related organelles in infected macrophages and dendritic cells. These viral secretory compartments move from an intracellular localization to an infectious synapse when infected macrophages or dendritic cells form an immunological synapse with activated T cells. This may be one mechanism for subsequent viral infection of CD4‐positive T cells, thus causing the impaired immune response seen in patients with acquired immunodeficiency syndrome (AIDS).

VI. The Cytoskeleton and Disease {#sec0020}
================================

Cells require a highly organized framework or cytoskeleton to station and move membrane organelles within three‐dimensional space. Components of the cytoskeleton can guide organelles or vesicles to specific destinations within the cell. The microtubule cytoskeleton is commonly associated with the directional movement of intracellular transport vesicles or intermediates. In contrast, actin has been envisioned to have a structural role in determining cell shape, plasma membrane dynamics, and cell locomotion. However, evidence points to a role for actin in regulated trafficking from the TGN ([@bib0003], [@bib0008], [@bib0056]) and endocytosis ([@bib0007], [@bib0096]).

The cytoskeleton is a dynamic structure likened to a collapsible scaffold that can be rapidly disassembled and reconstituted depending on cellular requirements. Actin or tubulin polymerization (elongation) and depolymerization (breakdown) rely on the controlled addition or removal of monomers in a polarized and energy‐dependent manner. Protofilaments in either structure are both polarized, with the plus end growing at a faster rate. Actin cables are each composed of two parallel protofilaments that twist around each other, whereas microtubules are composed of a hollow cylindrical structure comprising 13 parallel protofilaments.

Actin nucleation is an initial step required for elongation involving formation of a stable trimer subunit base for protofilament elongation. A heptameric complex termed ARP2/3 (actin‐related protein) binds to the ends and sides of actin filaments to nucleate and further accelerate the growth of the actin network ([@bib0228]). The function of the ARP2/3 complex can be regulated by membrane‐associated Rho GTPases. These regulators, which include Cdc42 and various Rac isoforms, act as molecular switches that cycle between an active GTP‐bound state and an inactive GDP‐bound state. Cdc42 regulates ARP2/3 indirectly through its downstream target Wiskott‐Aldrich syndrome protein (WASP), which binds directly to the ARP2/3 complex ([@bib0150]). Patients with X‐linked Wiskott‐Aldrich syndrome display mutations in the *WASP* gene and have thrombocytopenia (reduced platelet count), eczema, recurrent infections, hematologic malignancy, and autoimmune disorders ([@bib0189]). Approximately 300 disease mutations in *WASP* have been reported, which lead to defective control of WASP in actin polymerization and severe disease phenotypes ([@bib0037]). WASP expression is restricted to hematopoietic cells, although the ubiquitously expressed N‐WASP is present in various cells and tissues ([@bib0037]).

The actin network is important for the formation of immunological synapses between cytotoxic T lymphocytes (CTLs) and their targets, as well as T lymphocytes and antigen‐presenting cells such as macrophages. The formation of the immunological synapse in CTLs is essential for the transport, docking, and fusion of SLs and subsequent destruction of the target cell as described above. Defective WASP inhibits the formation of the immunological synapse and T cell activation ([@bib0252]), probably causing the immunological deficiencies observed in Wiskott‐Aldrich syndrome patients. WASP deficiency in T lymphocytes also affects the regulation and composition of lipid rafts ([@bib0088]), indicating that the formation of the immunological synapse is dependent on lipid rafts, WASP, and actin dynamics.

Motor proteins provide the physical force to move membrane vesicles along the polymerized cytoskeletal filaments via ATP‐dependent hydrolysis. Actin‐based motor proteins belong to the myosin superfamily. The myosin Va gene is mutated in a small number of patients with Griscelli syndrome ([@bib0009], [@bib0264]) (other trafficking mutations contributing to Griscelli syndrome are discussed in [Section V.C](#sec0019){ref-type="sec"}). Mutations in the myosin VIIa gene can cause Usher\'s syndrome, resulting in blindness and deafness. Intracellular transport is probably compromised in Usher syndrome patients; the mouse *shaker* model has a mutant myosin VIIa gene, displaying defective melanosome transport in retinal pigment epithelial cells ([@bib0203]) and altered distribution in photoreceptor cells ([@bib0287]).

Microtubule motor proteins, which actively move vesicles along the microtubules, and microtubule‐associated proteins (MAPs), serve as docking molecules to bind cargo to motor proteins ([@bib0117]). Microtubule motor proteins belong to either the kinesin or dynein families. With the exception of the C‐terminal kinesins, kinesin‐based motors generally transport cargo toward the plus end of the microtubule, whereas the dyneins are minus end‐directed motors.

Long‐range vesicular transport is particularly important in neurons, where axons can reach up to 1 m in length. Newly synthesized lipids, and secreted or membrane‐associated proteins, are made in the cell body; long‐range and directional transport is crucial for replenishing the constituents of the presynaptic cleft (at the terminal end of the axon) with synaptic vesicles and plasma membrane receptors ([@bib0141]).

A number of human neurological diseases are linked to mutations in microtubule motors and associated proteins. Lissencephaly, a Greek term meaning "smooth brain," causes severe brain malformation resulting in mental retardation and epilepsy. One of the genes mutated in the disease is LIS1 (originally identified in Miller‐Dieker syndrome patients with lissencephaly) ([@bib0286]). The LIS1 protein regulates microtubule motor function by binding dynein1 and p150^Glued^, a component of the dynactin complex that binds to and activates dynein ([@bib0327]). It is proposed that LIS1 regulates retrograde axonal transport. Another gene mutated in some patients with lissencephaly is doublecortin, a microtubule‐associated protein that binds tubulin and stabilizes microtubules ([@bib0143], [@bib0233]).

The KIF1B kinesin regulates transport of synaptic vesicle precursors along the neuronal axon. Patients with Charcot‐Marie‐Tooth disease type 2A display neuronal axonal degeneration due to a loss‐of‐function mutation in the motor domain of KIF1B ([@bib0399]). In Alzheimer\'s disease, a classical sign is hyperphosphorylated aggregates of the microtubule‐associated protein, tau, in neuronal cells and tissues. Tau protein can influence vesicular transport ([@bib0090]) by regulating the attachment of motors to microtubules ([@bib0359]). One theory is that the tau protein can interfere with kinesin‐dependent transport by blocking motor access to microtubules, thus slowing or preventing vesicle movement along axons ([@bib0217]). Moreover, an early sign of Alzheimer\'s disease is the loss of synapses and retrograde degeneration of neurons, complemented by a breakdown in intracellular transport.

The disruption of microtubule‐mediated vesicular trafficking may also be a causative factor of the neurodegenerative phenotype of Huntington\'s disease. This disease is caused by expansion of polyglutamine repeats occurring in the brain‐enriched protein Huntingtin (Htt). It has been demonstrated that Htt enhances vesicular transport of brain‐derived neurotrophic factor (BDNF) along microtubules ([@bib0116]). Htt is localized in the cytoplasm and is associated with vesicular and microtubule‐based traffic through its ability to bind Huntingtin‐associated protein 1 (HAP1) ([@bib0196]), a protein that has affinity for the dynactin p150^Glued^ subunit ([@bib0094]). Dysfunctional polyQ‐Htt associated with the disease state may disrupt the transport of BDNF by binding and blocking the HAP1/dynactin‐mediated delivery of BDNF vesicles along microtubules ([@bib0116]). This is further supported by the finding that BDNF levels are decreased in brains of Huntington\'s disease patients ([@bib0101]).

VII. Therapeutic Strategies {#sec0021}
===========================

A. Current Treatments {#sec0022}
---------------------

The current treatment of genetic disorders involves addressing the symptoms rather than the cause. To that end, many mild forms of disorders such as Niemann‐Pick disease, and familial hypercholesterolemia, can be controlled by diet regimens and lifestyle changes. In contrast, a life‐threatening disease such as cystic fibrosis requires extensive physiotherapy and pulmonary exercise to loosen and prevent mucus accumulation within the lungs.

New antidementia drugs are increasingly successful in treating neurological disorders such as Alzheimer\'s disease. Drugs such as galantamine, donepezil, rivastigmine, and memantine target the posttranslational processing of βAPP to reduce amyloid deposits ([@bib0280]). In familial hypercholesterolemia, statin treatment is a common strategy for reducing plasma LDL and cholesterol levels by targeting HMG‐CoA reductase, the rate‐limiting enzyme in cellular cholesterol biosynthesis. Furthermore, less commonly used LDL‐lowering drugs such as probucol have shown some success in lowering circulating lipoprotein and cholesterol levels ([@bib0034]). The administration of adrenalin receptor antagonists (β‐blockers) to patients with the cardiac condition long‐QT syndrome reduces arrhythmia risk. Enzyme replacement therapy (ERT) has been carried out in patients with Fabry\'s disease, a lysosomal storage disease. Patients are given recombinant lysosomal α‐galactosidase ([@bib0227]) to reduce the risks of strokes and kidney failure associated with the condition. Finally, organ transplantation is occasionally carried out for some disease states: for example, bone marrow transplants for Chediak‐Higashi syndrome patients ([@bib0197]) and Rab27a‐defective patients with Griscelli syndrome ([@bib0309]) and Wiskott‐Aldrich syndrome ([@bib0103]). However, although transplant operations can be successful in alleviating the immunological issues associated with these diseases, it does not address problems associated with the nervous system or pigmentation.

B. Gene Therapy: The Next Generation of Medical Treatment? {#sec0023}
----------------------------------------------------------

Completion of the human genome sequencing project has given science the ability to track gene(s) responsible for potentially any genetic disorder and, as a consequence, to allow these genes to be corrected in patients. This is the goal of gene therapy research. Of course, gene therapy has a fundamental limitation: it is only really suitable for single‐gene defect diseases, and multigenic or chromosomal defects will be beyond the ability of the technique because of the complex nature of the disease. However, there are more than 2500 single gene defects that cause human disease, so there are many diseases requiring such approaches. The history of gene therapy is discussed in more detail by [@bib0297], [@bib0311].

### 1. Gene Delivery {#sec0024}

Much effort has been made in developing techniques that allow successful replacement or augmentation of defective genes. Gene therapy is performed by introducing a gene vehicle directly into the patient (*in vivo*) or by removing cells from a patient, introducing the gene into these cells in culture, and replacing the cells back in the patient (*ex vivo*). Most studies have focused on the use of viral vectors as delivery vehicles.

Retroviruses are potentially the best gene delivery system ([@bib0179]). These RNA viruses are able to infect a great many cell types and replicate by inserting their viral genes into the genome of the host. The host cellular machinery is then modulated to produce and assemble viral particles. In gene therapy, retroviruses could be used to express the target gene to be replaced but be modified to prevent viral disease (HIV, which is the causative agent of AIDS, is also a retrovirus). The principal drawback of a retrovirus vector is the possibility that genomic integration could elevate oncogene expression, thus causing cancer. Therefore, the majority of clinical trials using retrovirus vectors have been performed *ex vivo*. A "successful" gene therapy experiment was exemplified in the case of a 4‐year‐old female patient lacking adenosine deaminase (ADA), which results in severely compromised immunodeficiency (ADA‐SCID) and dysfunctional T cells ([@bib0027]). In this case, a retroviral vector was used to deliver the coding sequence for ADA into cells, resulting in successful expression of this enzyme in hitherto defective cells. Although successful, it is uncertain whether enzyme replacement treatment (recombinant ADA injections) also influenced the patient outcome.

Adenovirus (AdV) ([@bib0222]) is a DNA virus and key gene therapy vehicle that maintains the viral genome as a separate transmissible episome within the nuclei of infected host cells. The use of attenuated or inactivated AdV for human gene delivery has attracted much interest. The advantages of AdV gene transfer are that its genome can easily be manipulated and recombinant virus can be grown to high titers *in vitro* with efficient transduction of target cells *in vitro* or *in vivo*. As AdV can effectively infect nondividing cells such as lung pulmonary tissues it is a popular vector of choice for gene therapy to treat cystic fibrosis (CF) patients. Although there are promising studies ([@bib0396]), failures have also been noted ([@bib0168]).

A major disadvantage of an AdV‐based approach is the triggering of a strong host immune response to the virus, which becomes a serious problem in subsequent long‐term delivery of recombinant virus for disease alleviation. One approach to circumventing such an issue is to use a viral delivery system that produces a low host immune response such as the adeno‐associated virus (AAV) ([@bib0104]). AAV is a nonpathogenic virus that requires coinfection with a helper virus to replicate. However, AAV has broad host cell specificity and is difficult to grow in large quantities, probably because of its reliance on a helper virus.

Finally, nonviral methods are increasingly available for the delivery of DNA constructs directly into cells and tissues. These are often lipid‐based reagents (e.g., liposomes) that bind to the plasmid DNA and fuse with the plasma membrane, thus enabling cytosolic delivery of the gene. The plasmid DNA would then be transported into the host nucleus by endogenous cellular machinery. This type of gene delivery can only be performed *ex vivo* and can be limited by the poor DNA transfection efficiency of primary cells or tissues. This type of method, however, is a potentially useful method for delivering genes into progenitors or precursors (e.g., stem cells) before cellular differentiation and tissue formation within a particular microenvironment in the body ([@bib0226]).

C. Other Potential Therapeutic Methods {#sec0025}
--------------------------------------

### 1. Chemical and Pharmacological Chaperones {#sec0026}

Numerous disease states are caused by protein misfolding within the ER, leading to degradation ([Table I](#tbl0001){ref-type="table"}; [1](#sec0005){ref-type="sec"}, [2](#sec0006){ref-type="sec"}). One strategy would be to promote the correct protein conformation in a mutant gene product either chemically or pharmacologically. A number of membrane‐diffusible chemical and pharmacological "chaperones" have been identified that could affect protein folding in cells. Chemical chaperones such as glycerol and trimethylamine *N*‐oxide (TMAO) can restore the wild‐type trafficking and activity of CFTRΔF508 in cultured epithelial cells ([@bib0032]), and porcine kidney epithelial cells expressing CFTRΔF508 and treated with dimethyl sulfoxide (DMSO) increased plasma membrane levels of the channel protein ([@bib0017]). [@bib0205] have demonstrated that a novel quinazoline derivative specific for CFTR will rescue the defective trafficking of CFTRΔF508 in cultured cells. Cell surface levels of a water channel, aquaporin‐2, can be enhanced with DMSO ([@bib0348]). Defects in this gene can result in X‐linked nephrogenic diabetes insipidus, a condition in which patients are unable to concentrate their urine because of an inability to reabsorb water from the kidneys into the blood.

Although chemical chaperones are somewhat nonspecific in their action (the protein folding of the whole cell is affected and not just the target protein), pharmacological chaperones can be tailored to individual proteins. For example, the compound SR121463A is a nonpeptide vasopressin V2 receptor antagonist ([@bib0235], [@bib0289]). Patients with a mutant vasopressin V2 receptor can also display nephrogenic diabetes insipidus. On treatment, the cell‐permeant SR121463A compound would act as a chaperone and accompany the mutant V2 receptor to the cell surface to rescue correct functionality.

Geldanamycin, a naturally occurring antifungal agent, has potential as an anticancer drug ([@bib0018], [@bib0232]). Geldanamycin interacts with and inhibits activity of the heat shock protein and chaperone Hsp90, a cytosolic cellular stress protein that supports the correct folding, stability, and function of "client" proteins. Many Hsp90 client proteins are implicated in cell cycle progression, proliferation, and angiogenesis ([@bib0375]). The ErbB2 tyrosine kinase complex is implicated in regulation and development of epithelial breast tumors and is an Hsp90 client. Inhibition of Hsp90 action by geldanamycin results in degradation of both ErbB2 and downstream signaling effectors, resulting in reduced cellular growth and tumor formation ([@bib0051]).

### 2. Cell‐Penetrating Peptides {#sec0027}

A number of cell‐permeable peptide sequences found in viruses and host proteins have been discovered that mediate the delivery of cargo (proteins, drugs, plasmid DNA, oligonucleotides) directly into cells ([@bib0031], [@bib0124], [@bib0310]). Such peptide sequences could be fused or attached to recombinant or engineered proteins and administered to patients to complement defects of a particular gene product. For example, the *Drosophila melanogaster* antennapedia homeodomain (Antp) transcription factor contains a short 16‐residue sequence that mediates protein translocation across biological membrane bilayers in an energy‐independent manner ([@bib0075], [@bib0152]).

Other sources of cell membrane‐permeable proteins have been uncovered in viruses. The HIV‐1 replication protein Tat contains a basic, arginine‐ and lysine‐rich peptide sequence (residues 47--57) that modulates the translocation of exogenous Tat across the plasma membrane in a number of cell types, and is able to activate intracellular genes controlled by an HIV promoter ([@bib0109], [@bib0218]). This basic 10‐residue sequence can internalize conjugated β‐galactosidase and horseradish peroxidase ([@bib0099]) as well as a Fab antibody fragment ([@bib0006]). The major structural protein of herpesvirus (HSV‐1), VP22, can traffic between cells ([@bib0092]), whereas the PreS‐2 domain of hepatitis B virus surface antigen acts as a shuttle for peptides and functional proteins (such as EGFP) in hepatocytes and other cells ([@bib0255]), suggesting further the existence of naturally occurring peptide sequences that may act as drug delivery vectors. Finally, a "synthetic" amphipathic peptide, FLUOS‐KLALKLALKALKAALKLA‐NH~2~, has been shown to be internalized in mast and endothelial cells ([@bib0254]).

### 3. Small Molecule Therapeutics {#sec0028}

The employment of small molecular inhibitors as a method of treating human disease has moved at exponential pace. A number of compounds have been synthesized or isolated from nonhuman organisms that directly affect cellular function and have been used in research on a variety of diseases. Plant‐ and microorganism‐derived polyhydroxylated alkaloids referred to as iminosugars have been used in the treatment of patients with Gaucher disease ([@bib0061]). Gaucher disease type I and type II is a lysosomal storage disorder caused by a mutation in the gene encoding the acid β‐glucosidase (GBA) enzyme and results in the accumulation of toxic glucosylceramide in a patient\'s spleen, liver, and bones; manifesting itself in enlargement of these organs, as well as heart and lung disease. Iminosugars act on glycosylating enzymes present within the ER and Golgi and inhibit their ability to transfer sugar moieties onto proteins. One member of the iminosugar family, *N*‐butyldeoxynojirimycin (NB‐DNJ; also called miglustat or Zavesca) inhibits the enzyme important in the maturation of the GBA substrate glucocerebroside, namely ceramide glucosyltransferase (CGT) ([@bib0039]). Inhibition of CGT has resulted in significantly reduced levels of glucocerebroside in the liver and spleen of patient in clinical trials ([@bib0061]). However, nearly 80% of patients in the trials displayed osmotic diarrhea as a side effect of the treatment. In a mouse model for human Tay‐Sachs disease, which is caused by a mutation in the gene encoding hexosamidase A, levels of the harmful glycophospholipid GM~2~ were significantly reduced on treatment with NB‐DNJ ([@bib0277]). In addition to the treatment of lysosomal storage diseases, an NB‐DNJ derivative called miglitol has been used in the treatment of diabetes mellitus, resulting in reduced activity of the sucrose--isomaltase enzyme complex and reduction of carbohydrate digestion ([@bib0230]).

A major aspect of human disease is the production and subsequent degradation of misfolded proteins, either by the proteasome or within the lysosome. Lysosomotropic agents such as chloroquine cause an increase in the intralumenal pH of endosomes and lysosomes, reducing lysosomal protease activities and the trafficking of proteins through the endosome--lysosome system. A number of proteasome inhibitors such as MG132, lactacystin, and ALLN can specifically inhibit the activity of a range of serine and cysteine proteases and chymotrypsin‐like enzymes ([@bib0166]). Proteasome inhibition has been linked with a number of aspects of human disease. Treatment of endothelial cells with proteasome inhibitors resulted in apoptosis of proliferating cells ([@bib0083]) and inhibition of plasminogen activator levels; this factor promotes angiogenesis and new blood vessel sprouting ([@bib0257]). However, inhibiting proteasome function has broad cytotoxic and apoptotic effects in cells and tissues.

Chemotherapeutic agents targeting signaling pathways are currently of much interest in relation to cancer therapeutics. Cellular proliferation can be regulated by growth factor binding to a cell surface receptor and signaling through either the mitogen‐activated protein kinase (MAPK) or phosphoinositide‐3‐kinase (PI3K) cascades. Activation of these pathways induces the expression of oncogenes such as c‐*jun* and c‐*fos* and inhibits apoptosis through a sequence of protein phosphorylation events. [@bib0320] demonstrated that inhibition of the MAPK pathway with small molecule inhibitors specific for Raf‐1 or MEK reduced cell proliferation and induced apoptosis in conditionally transformed hematopoietic cells. However, such pathways also regulate other cellular functions besides proliferation or apoptosis and there are likely to be consequences for cellular homeostasis.

Structural studies are important in the development of new small molecule inhibitors that target specific enzymes and regulators. c‐Akt (PKB) is a serine/threonine protein kinase required for survival and proliferation in many human cancers and its structure has been elucidated ([@bib0177], [@bib0391]; and references therein). Chemotherapeutic agents have been consequently designed that inhibit c‐Akt activity; molecules such as H‐89 target the ATP‐binding pocket in c‐Akt ([@bib0177]). Compounds that bind specifically to c‐Akt isoforms or target specific domains within the kinase have been reported ([@bib0012]), but there are no reports of clinical trials with such compounds ([@bib0177]).

Finally, small molecule inhibitors are being developed to target the posttranslational processing of proteins or peptides implicated in human disease. The enzyme that catalyzes the initial steps in β‐amyloid synthesis, γ‐secretase, is an attractive target for prevention of amyloid deposits in Alzheimer\'s disease patients ([@bib0050]). Such small molecule inhibitors could also be used to treat pathogenic infections such as those caused by severe acute respiratory syndrome (SARS), influenza, HIV, or hepatitis C viruses. Attractive targets are virus‐encoded or host proteases required for processing of viral proteins to generate infectious virus particles from the host cell. In the case of the SARS virus, a viral chymotrypsin‐like cysteine protease is responsible for processing SARS viral proteins required for viral replication. Inhibition of this protease would effectively inhibit viral replication. A molecule referred to as CS11 was found to inhibit the replication of human SARS with no toxic effect on normal cells ([@bib0081]). Much work is also being carried out in targeting host proteases required for the processing of HIV envelope glycoproteins by the biosynthetic secretory pathway to generate viral gp120 and gp41 polypeptides.

VIII. Concluding Remarks {#sec0029}
========================

The completion of the human genome sequencing project has led to the prediction that a large number of diseases will be identified and understood at the gene level ([@bib0058]). As noted in this review, a number of examples exist in which a single gene mutation can have devastating effects on human function. At present, the symptoms of some mild forms of genetic diseases can be modulated through diet or drug regimens, and some success has been achieved with organ transplantation. Gene therapy has attracted much attention but has suffered setbacks due to viral toxicity issues. An alternative strategy is the use of small molecule therapeutics, which may override specific defects or target specific pathways to compensate for gene defect(s). In addition, our understanding of how we respond at a genetic level to pathological infection will enable us to design effective drug strategies to presently chronic infections. In essence, understanding the cell biological basis for human diseases will enable us to design effective methods to deliver therapeutic strategies to patients.

[^1]: G. J. Howell and Z. G. Holloway contributed equally to this work.
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